Send Message
View as an RSS Feed
  • Amarin Update After CC  [View instapost]
    My WAG is Sept update. RSUs were given to CEO, president and lead general counsel on 7/26 for meeting certain performance criteria. Guessing that the criteria met was NCE
    Aug 18, 2013. 08:23 PM | Likes Like |Link to Comment
  • All Eyes Now Focusing On Acquisition Of Amarin  [View instapost]
    PFE is also divesting its 80% stake in Zoetis, the deal to be closed by June 19. PFE received $2 billion for the first 20% it sold in the Feb. Zoetis IPO. It will be an exchange offer subject to certain restrictions, one of which is the exchange of a minimum of 160,394,000 shares, up to a total of 400,985,000 shares. That 40% minimum gives them at least $4 billion +, and if they divest all the shares upwards of $8-9 billion. They announced this on May 22. The AZN deal is announced 6 days later. So PFE has the money. The timing seems about right too.
    May 29, 2013. 08:16 AM | 5 Likes Like |Link to Comment
  • Alexza's Staccato: Setting Up as a New Platform for 'Inhalation Technology'  [View article]
    The FDA issued cease and desist letters to sellers of the e-cigarettes, as it wants to control the use of nicotine used by these devices.

    ALXA has already licensed its Staccato Nicotine technology to Cypress for $5 million up front, $1 million next year, and Cypress has agreed to pay for all the Phase trials. ALXA will keep a 10% carry of all the assets associated with Staccato Nicotine in the future, including worldwide rights to a smoking cessation product.

    E-cigarettes have nothing to do with the Staccato Loxipine NDA, nor will the FDA consider it in its decision for approval. ALXA has conducted numerous safety studies that address any concerns the FDA might have.

    Anyone trying to tie the two technologies together is either misinformed or wants you to be misinformed, as one has nothing to do with the other.
    Sep 23, 2010. 09:04 PM | Likes Like |Link to Comment